Abivax Slips as Investors Weigh Regulatory Timing After Recent Updates

Abivax (ABVX) is down 3.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The pullback appears tied to a mix of biotech profit-taking and a more tempered view of the company’s regulatory timeline following recent business updates. While Abivax has highlighted continued progress for obefazimod and upcoming scientific presentations, the market may be focusing more on a standard review path and the idea that much of the near-term good news is already reflected in the stock.

Details:

Abivax said in its recent half-year update that obefazimod remains its lead asset in ulcerative colitis and that the company is advancing toward a planned NDA submission in the fourth quarter of 2026.

The same update showed a stronger cash position after the summer equity raise, giving the company runway into late 2029, which supports development but does not remove execution and approval risk.

A recent analyst note lowered a price target while keeping a neutral stance, pointing to a standard review timeline rather than a faster path, which can cool momentum in biotech shares.

Abivax also announced seven scientific abstracts for an October medical meeting, but conference presentations often help sentiment more than they provide an immediate trading catalyst unless new data materially changes the outlook.

Sources:

SEC, Abivax, TipRanks

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive ABVX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$ABVX Hedge Fund Activity

We have seen 181 institutional investors add shares of $ABVX stock to their portfolio, and 130 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

HELIKON INVESTMENTS LTD added 2,787,131 shares (+inf%) to their portfolio in Q2 2026, for an estimated $371,413,077
UBS GROUP AG removed 2,702,488 shares (-59.4%) from their portfolio in Q2 2026, for an estimated $360,133,550
RA CAPITAL MANAGEMENT, L.P. added 1,132,557 shares (+inf%) to their portfolio in Q2 2026, for an estimated $150,924,545
NORGES BANK added 1,100,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $146,586,000
FMR LLC removed 1,094,684 shares (-85.1%) from their portfolio in Q2 2026, for an estimated $145,877,589
BAKER BROS. ADVISORS LP removed 875,796 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $116,708,574
VESTAL POINT CAPITAL, LP added 849,443 shares (+56.6%) to their portfolio in Q2 2026, for an estimated $113,196,774

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ABVX Analyst Ratings

Wall Street analysts have issued reports on $ABVX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 06/30/2026

To track analyst ratings and price targets for $ABVX, check out Quiver Quantitative's $ABVX forecast page.

$ABVX Price Targets

Multiple analysts have issued price targets for $ABVX recently. We have seen 8 analysts offer price targets for $ABVX in the last 6 months, with a median target of $156.5.

Here are some recent targets:

Allison Bratzel from Piper Sandler set a target price of $175.0 on 07/09/2026
Gregory Renza from Truist Securities set a target price of $155.0 on 07/02/2026
Jason N. Butler from Citizens set a target price of $187.0 on 07/01/2026
Julian Harrison from BTIG set a target price of $175.0 on 06/30/2026
David Nierengarten from Wedbush set a target price of $110.0 on 06/30/2026
Thomas Smith from Leerink Partners set a target price of $148.0 on 06/30/2026
Faisal Khurshid from Jefferies set a target price of $158.0 on 06/30/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.